Roche (OTCMKTS:RHHBY) Stock Price Breaks Below 50-Day Moving Average – Should You Sell?

Roche Holding AG (OTCMKTS:RHHBY) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $55.11 and traded as low as $51.83. Roche shares last traded at $52.25, with a volume of 640,963 shares traded.

Analysts Set New Price Targets

RHHBY has been the topic of several research analyst reports. Royal Bank Of Canada began coverage on shares of Roche in a research note on Tuesday, September 8th. They set an “outperform” rating on the stock. HSBC reiterated a “hold” rating on shares of Roche in a research note on Thursday, September 10th. Morgan Stanley upgraded shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price objective on the stock in a research report on Friday, August 7th. Finally, Zacks Research upgraded shares of Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Roche currently has an average rating of “Moderate Buy” and an average target price of $60.00.

Roche Stock Performance

The firm has a 50-day simple moving average of $55.11 and a 200-day simple moving average of $52.39. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.23 and a quick ratio of 0.95.

Hedge Funds Weigh In On Roche

Institutional investors and hedge funds have recently made changes to their positions in the business. Puzo Michael J bought a new position in Roche in the second quarter worth approximately $1,229,000. North Star Asset Management Inc. purchased a new position in shares of Roche during the 2nd quarter worth $1,351,000. S&CO Inc. grew its position in shares of Roche by 163.0% during the 1st quarter. S&CO Inc. now owns 140,551 shares of the company’s stock valued at $6,880,000 after acquiring an additional 87,107 shares during the period. Opal Capital LLC bought a new stake in shares of Roche during the 1st quarter valued at $4,448,000. Finally, PNC Financial Services Group Inc. increased its stake in shares of Roche by 5.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 23,456 shares of the company’s stock worth $1,166,000 after purchasing an additional 1,201 shares in the last quarter.

Roche Company Profile

Roche Holding AG is a Swiss healthcare company headquartered in Basel, Switzerland. Founded in 1896, the company operates through two core divisions: Pharmaceuticals and Diagnostics. Roche develops medicines and diagnostic technologies intended to support disease prevention, detection, diagnosis and treatment.

Roche’s pharmaceutical activities focus on areas including oncology, immunology, neuroscience, ophthalmology, hematology and rare diseases. Its portfolio includes biologic and small-molecule medicines, as well as individualized healthcare approaches that use diagnostic information to help guide treatment decisions.

Through its Diagnostics division, Roche provides in vitro diagnostic systems, molecular testing, tissue-based diagnostics, diabetes-care products and laboratory solutions for healthcare providers, laboratories and patients.